New progress in immunotherapy of lung cancer

He Cao,Jianya Zhou
DOI: https://doi.org/10.3760/cma.j.issn.1673-436X.2016.15.012
2016-01-01
Abstract:Lung cancer is one of the most common malignant tumors,is the leading cause of the tumor-related death in the world.The standard therapy is currently the chemotherapeutic regimes with the basis of platinum.If the patients' conditions advance,the choice of thrapy is limitted.In recent years,researchers have paid more attention to immunotherapy,this kind of treatment contains tumor vaccines,programmed death-1(PD-1),cytotoxic T lymphocyte antigen-4 (CTLA-4) and so on.The research data have supported the immunotherapy effect.This article reviews the mechanism of anti-tumor vaccines,PD-1,CTLA-4 inhibitors,shows some results about immunotherapy agents in recent series of clinical trials,discusses the biomarkers for predicting the efficacy of immune drugs,introduces the potential problems and directions of future treatment.
What problem does this paper attempt to address?